File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1111/ajco.14074
- Scopus: eid_2-s2.0-85193852625
- Find via
Supplementary
-
Citations:
- Scopus: 0
- Appears in Collections:
Article: Current practices and challenges in genetic testing and counseling for women with breast and ovarian cancer in Asia
Title | Current practices and challenges in genetic testing and counseling for women with breast and ovarian cancer in Asia |
---|---|
Authors | |
Keywords | Asia breast neoplasms genetic counseling genetic testing ovarian neoplasms |
Issue Date | 22-May-2024 |
Publisher | Wiley |
Citation | Asia-Pacific Journal of Clinical Oncology, 2024 How to Cite? |
Abstract | Aim: This study assesses current practices and challenges in genetic testing and counseling (GT and C) for breast cancer gene (BRCA)1/2 mutations in Asia, considering the increased risk of ovarian cancer (OC) and breast cancer (BC) in women carrying these mutations. Methods: Insights were gathered through a questionnaire from breast surgeons, gynecologists, oncologists, and genetic clinicians in 10 Asian countries: Thailand, Hong Kong, South Korea, India, Vietnam, Malaysia, the Philippines, Taiwan, Singapore, and Indonesia. The questionnaire covered their knowledge, attitudes, and practices in GT and C for BRCA1/2 mutations, along with information on perceived gaps and unmet needs in the region. Results: A total of 61 specialists participated in the survey. GT and C for BRCA1/2 mutations were less frequently offered in Asia compared to Western countries. Among the guidelines used, the National Comprehensive Cancer Network (NCCN) guidelines alone or in combination with other guidelines (American Society of Clinical Oncology [ASCO], National Institute for Health and Clinical Excellence [NICE], and European Society for Medical Oncology [ESMO]) were preferred for both BC and OC. Limited access to genetic counselors posed a significant challenge, resulting in delayed or no GT. Pretest genetic counseling was provided by the respondents themselves. Germline testing was preferred for BC, whereas both germline and somatic testing were preferred for OC, with the most preferred option being a multipanel germline test. Conclusion: Disparities exist in GT and C practices between Asian and Western countries. To address this, steps, such as patient and doctor education, increased accessibility and affordability of GT and C services, and improved infrastructure for identifying gene mutations, should be taken. |
Persistent Identifier | http://hdl.handle.net/10722/344216 |
ISSN | 2023 Impact Factor: 1.4 2023 SCImago Journal Rankings: 0.531 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwong, Ava | - |
dc.contributor.author | Tan, David S‐P | - |
dc.contributor.author | Ryu, Jai Min | - |
dc.contributor.author | ACROSS Consortium | - |
dc.date.accessioned | 2024-07-16T03:41:43Z | - |
dc.date.available | 2024-07-16T03:41:43Z | - |
dc.date.issued | 2024-05-22 | - |
dc.identifier.citation | Asia-Pacific Journal of Clinical Oncology, 2024 | - |
dc.identifier.issn | 1743-7555 | - |
dc.identifier.uri | http://hdl.handle.net/10722/344216 | - |
dc.description.abstract | <p>Aim: This study assesses current practices and challenges in genetic testing and counseling (GT and C) for breast cancer gene (BRCA)1/2 mutations in Asia, considering the increased risk of ovarian cancer (OC) and breast cancer (BC) in women carrying these mutations. Methods: Insights were gathered through a questionnaire from breast surgeons, gynecologists, oncologists, and genetic clinicians in 10 Asian countries: Thailand, Hong Kong, South Korea, India, Vietnam, Malaysia, the Philippines, Taiwan, Singapore, and Indonesia. The questionnaire covered their knowledge, attitudes, and practices in GT and C for BRCA1/2 mutations, along with information on perceived gaps and unmet needs in the region. Results: A total of 61 specialists participated in the survey. GT and C for BRCA1/2 mutations were less frequently offered in Asia compared to Western countries. Among the guidelines used, the National Comprehensive Cancer Network (NCCN) guidelines alone or in combination with other guidelines (American Society of Clinical Oncology [ASCO], National Institute for Health and Clinical Excellence [NICE], and European Society for Medical Oncology [ESMO]) were preferred for both BC and OC. Limited access to genetic counselors posed a significant challenge, resulting in delayed or no GT. Pretest genetic counseling was provided by the respondents themselves. Germline testing was preferred for BC, whereas both germline and somatic testing were preferred for OC, with the most preferred option being a multipanel germline test. Conclusion: Disparities exist in GT and C practices between Asian and Western countries. To address this, steps, such as patient and doctor education, increased accessibility and affordability of GT and C services, and improved infrastructure for identifying gene mutations, should be taken.</p> | - |
dc.language | eng | - |
dc.publisher | Wiley | - |
dc.relation.ispartof | Asia-Pacific Journal of Clinical Oncology | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Asia | - |
dc.subject | breast neoplasms | - |
dc.subject | genetic counseling | - |
dc.subject | genetic testing | - |
dc.subject | ovarian neoplasms | - |
dc.title | Current practices and challenges in genetic testing and counseling for women with breast and ovarian cancer in Asia | - |
dc.type | Article | - |
dc.identifier.doi | 10.1111/ajco.14074 | - |
dc.identifier.scopus | eid_2-s2.0-85193852625 | - |
dc.identifier.eissn | 1743-7563 | - |
dc.identifier.issnl | 1743-7555 | - |